To compare time to retreatment and visual function between patients with treatment-naïve
neovascular age-related macular degeneration (AMD) treated with either intravitreal
ranibizumab (IVR) or intravitreal aflibercept (IVA) in routine clinical practice.
Retrospective, interventional comparative case series.
A total of 200 eyes of 197 patients with neovascular AMD.
A total of 99 patients in the IVR group and 101 patients in the IVA group who met
the inclusion criteria with 12 months of follow-up were included in the present study.
All patients received 3 consecutive monthly injections of 0.5 mg/0.05 mL ranibizumab
or 2.0 mg/0.05 mL aflibercept as loading doses. Retreatment was allowed if evidence
of clinical deterioration or the presence of intraretinal edema or subretinal fluid
on spectral-domain optical coherence tomography examination performed at the 1-month
follow-up was noted. The time to retreatment after the third injection during the
loading phase to the first recurrence during the maintenance phase was compared between
treatments using the Kaplan-Meier analysis. Functional and anatomic outcomes were
also compared between the IVR and IVA groups.
The median time to retreatment after the last induction dose was 5 months in both
groups. The proportion of IVR patients who required injection retreatment was not
significantly higher than that of IVA patients (67.7% and 63.4%, respectively, at
the 12-month follow up; log-rank test, P = .554). In both groups, significant improvements in postoperative best-corrected
visual acuity (BCVA) compared with preoperative visual acuity was observed over the
12-month follow-up period (P < .05 for both). Central foveal thickness (CFT) decreased from the baseline values
in both groups during the follow-up period (P < .001 for both). Although there was a trend toward greater BCVA improvements in
the IVA group, no significant differences in BCVA or CFT were observed between the
Both IVR and IVA were well tolerated and demonstrated efficacy in improving the visual
acuity in treatment-naïve patients with AMD. Despite a trend toward greater BCVA improvements
in the IVA group, a similar injection burden was observed following the loading phases
of both ranibizumab and aflibercept.